RALA and lung carcinoma: The notion that FAM3C is a novel bona fide binding partner of RalA was supported by multiple converging lines of evidence: First, we observed in immunoblot assays that FAM3C expression correlated with levels of total and especially phosphorylated RalA (Ser194) across an array of lung carcinoma cell lines (Figure 6A, left).